DR info

Clinical trials : 25 / Drugs : 23 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 9

Drugs and their primary sponsors and trial info

Glucose
   University Hospital, Toulouse
      2015   -   NCT02383316   France;
Lamotrigin beta
   Technische Universität München, Fakultät für Medizin
      2018   Phase 2   EUCTR2016-005022-10-DE   Germany;
MAXOMAT ®, biosynthetic growth hormone
   Sanofi
      1997   Phase 3   NCT00452725   France;
MEK162
   Array Biopharma, now a wholly owned subsidiary of Pfizer
      2012   Phase 2   NCT01556568   United Kingdom;United States;
   Novartis Pharma Services AG
      2012   -   EUCTR2011-003392-10-GB   United Kingdom;United States;
Norditropin 24 IU
   Novo Nordisk A/S
      2005   -   EUCTR2005-000042-37-SE   Sweden;
Norditropin SimpleXx
   Novo Nordisk A/S
      2005   -   EUCTR2005-000042-37-SE   Sweden;
RhIGF-1/rhIGFBP-3
   Insmed Incorporated
      2006   Phase 2   NCT00351221   United States;
Simvastatin
   University Hospital Toulouse
      2016   Phase 3   EUCTR2016-000647-14-FR   France;
   University Hospital, Toulouse
      2017   Phase 3   NCT02713945   France;
Somatropin
   Novo Nordisk A/S
      2018   -   NCT03435627   Japan;
      2013   Phase 3   NCT01927861   Japan;
      2008   Phase 3   NCT01529944   Sweden;
      2006   -   NCT00960128   Argentina;Belgium;Brazil;Czech Republic;Czechia;Denmark;Finland;Former Serbia and Montenegro;France;Germany;Hungary;Ireland;Israel;Italy;Lithuania;Luxembourg;Netherlands;Norway;Russian Federation;Saudi Arabia;Serbia;Slovenia;Spain;Sweden;Switzerland;United Kingdom;
      2005   -   EUCTR2005-000042-37-SE   Sweden;
      1990   Phase 3   NCT01529840   Sweden;